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According to the authors and editors, this report contains the most justified principles of diagnostic and therapeutic 
procedures prepared considering the scientific value of evidence and category of recommendations. These principles 
should always be interpreted in the context of an individual clinical situation. The recommendations do not always 
correspond to the current reimbursement rules in Poland. In case of doubt, the current possibilities of reimbursement 
of individual procedures should be established.
1. The quality of scientific evidence
I — Scientific evidence obtained from well-designed and conducted randomized clinical trials or meta-analyses of 
randomized clinical trials
II — Scientific evidence obtained from well-designed and conducted prospective observational studies (non-randomized
cohort studies)
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III — Scientific evidence obtained from retrospective observational studies or case-control studies
IV — Scientific evidence obtained from clinical experiences and/or experts, opinions
2. Category of recommendations
A — Indications confirmed unambiguously and absolutely useful in clinical practice
B — Indications probable and potentially useful indications in clinical practice
C — Indications determined individually
Introduction
Skin cancers, with basal cell carcinoma (BCC) and 
squamous cell carcinoma (SCC), responsible for about 
98% of all skin cancers, are the most common malignan-
cies in the Caucasian population. Skin carcinomas, also 
defined as non-melanoma skins cancers (NMSC), are 
responsible for about 1/3 of all new cancer diagnoses 
in men. 
Despite low metastatic potential and relatively 
low death risk associated with NMSC, they remain 
a significant clinical challenge. Skin carcinomas are 
characterised by local aggressiveness and a tendency 
to infiltrate surrounding structures, such as bones and 
cartilages. Aesthetic defects resulting from such damage 
significantly impair long-term quality of life and arise as 
an important social problem due to the high prevalence 
of NMSC. Among patients within the high-risk group 
(e.g. immunocompromised patients or those with a ge-
netic predisposition to develop UV radiation-induced 
cancers), the course of the disease is different because 
skins carcinomas in these patients are more aggressive 
and often result in death. Additionally, patients with 
a history of skin cancer have elevated risk of developing 
other cancers, including melanoma, when compared to 
the general population. 
Due to limited space, the presented manuscript does 
not cover the topic of premalignant skin lesions (such as 
actinic keratosis) or squamous and basal cell carcinomas 
originating from urogenital organs, nail bed, and oral 
cavity [1–13].
Epidemiology
Skin carcinomas are responsible for 75% of all 
newly diagnosed cancer cases. Absolute risk of a skin 
cancer diagnosis during a lifetime exceeds 20% in the 
Caucasian population. Morbidity rises with age, with 
the highest prevalence in the 8th decade of life. In 2011 
in Poland 11,439 new cases (5408 in males and 6031 
in females) of skin carcinomas were registered, which 
results in morbidity of, respectively, 7.5% and 8.3%. 
Unfortunately, skin carcinomas might be significantly 
under-registered within the National Cancer Registry 
(Krajowy Rejestr Nowotworów), and estimated morbi-
dity might be underrated.
The most common type of skin carcinoma is basal 
cell carcinoma (BCC), which represents about 80% of 
cases. The second most common type is squamous cell 
carcinoma (SCC), responsible for the next 15–20% of 
cases [10, 13]. Other forms of skin carcinoma are less 
common [1–13]. 
Basal cell and squamous cell skin 
carcinomas
Risk factors
The rising prevalence of both BCC and SCC is mostly 
caused by excessive ultraviolet (UV) radiation exposure. 
Risk factors responsible for the rising BCC and SCC 
morbidity include: lifestyle changes in modern society; 
popularity of tanning; migration of people with skin phe-
notypes I, II, and III to regions with high sun exposure; 
living at high altitudes and nearer the equator; and usage 
of tanning lamps emitting UV radiation (“solariums”). 
Significant risk might be attributed to occupational 
exposure to UV radiation in people working outside and 
not utilising any form of photoprotection [1–11]. Table 1 
summarises risk factors associated with developing skin 
carcinomas. 
Hedgehog (Hh) pathway activation is present in 
most BCC cases, usually through inactivation of PTCH1 
(Patched 1) receptor or oncogenic activation of SMO 
(Smoothened) receptor. In Gorlin-Goltz syndrome 
(naevoid basal cell syndrome), an autosomal dominant 
disease characterised by a multifocal development of 
BCC, presence of facial and skeletal abnormalities, and 
an increased risk of medulloblastoma and rhabdomy-
osarcoma development, abnormalities in gene coding 
PTCH1 receptor are present. 
Diagnosis
Initial diagnosis is based on physical examination and 
characteristic clinical appearance of BCC/SCC lesions. 
About 80% of skin carcinomas arise within the head and 
neck; the remaining 20% usually localise within torso 
and extremities.
Skin carcinomas often arise multifocally, especially 
in patients older than 70 years, with a high degree of 
skin injury based on UV radiation and a long-term 
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Table 1. Skin carcinoma risk factors [1, 2]
Risk factor SCC BCC
Environ- 
mental  
factors
Cumulative UV dose ×
Intensive intermittent 
sunbathing
×
Ionising radiation × ×
Exposure to chemical 
substances*
× (×)
HPV infection ×
Nicotinism ×
Genetic  
factors
Skin phenotype I × ×
Xeroderma pigmentosum × ×
Oculocutaneous albinism × (×)
Epidermodysplasia verruciformis ×
Epidermolysis bullosa ×
Ferguson-Smith syndrome ×
Muira-Torre syndrome × (×)
Bazex syndrome ×
Rombo syndrome ×
Gorlin-Goltz syndrome ×
Chronic  
skin  
diseases
Chronic ulcerations/wounds ×
Long-term active:
— skin lupus erythematosus
— lichen planus (erosive) 
— lichen sclerosus
×
Porokeratosis ×
Nevus sebaceous ×
Immuno- 
suppression
Prior transplant recipient × (×)
Other forms of 
immunosuppression, e.g. AIDS 
syndrome or HPV infection
×
*Chemical substances: arsenic, mineral oil, coal tar, soot, nitric yperite, aro-
matic polycyclic compounds — biphenyl derivatives, 4,4’bipyridine, psoralen 
(including UVA) [1–11]. BCC — basal cell carcinoma; SCC — squamous cell 
carcinoma; HPV — human papilloma virus
history of growing lesions because most BCC enlarge 
slowly. In some cases, the presence of multiple BCC 
lesions, along with numerous areas of actinic kerato-
sis and Bowen disease, or even melanomas, might be 
coincident. Due to this, patients with NMSC should 
undergo a full and precise physical examination, 
including evaluation of the whole skin area. Because 
dermatoscopy has proven its value in several publi-
cations dedicated to the early diagnosis of cancer, 
this fast and affordable diagnostic modality should 
be considered as a standard part of clinical examina-
tion skin carcinoma is suspected. Dermatoscopy can 
provide essential value in untypical cases requiring 
differential diagnosis, in evaluation of smaller lesions 
or in differentiating between actinic keratosis and 
early SCC (in situ). Evaluation of cancer expansion 
before treatment initiation, assessment of treatment 
radicality, and monitoring after the treatment might 
also benefit from routine incorporation of dermato-
scopy (Tables 2, 3).
The most important part of diagnosis is the pa-
thological examination of specimens obtained by an 
excision or a biopsy. A pathology report should inc-
lude not only the histological type of carcinoma but 
should also define the specific subtype (especially in 
cases of high-risk subtype). The maximal size of the 
lesion and the depth of invasion should be evaluated 
in invasive carcinomas. Assessment of surgical margins 
is necessary. Presence of vascular and/or perineural 
invasion provides additional data regarding diagnosis 
and prognosis. In cases of uncertain histopathological 
type (BCC vs. SCC), the pathological examination 
should include at least a basic immunohistochemical 
panel [BerEP4(+) CK5/6(–) in BCC and BerEP4(–), 
CK5/6(+) in SCC]. 
Histopathological type of carcinoma, stage of dise-
ase, and patient’s performance status are essential when 
deciding on further care. In cases strongly suspicious 
from a clinical perspective, radical resection should be 
preferred. Clinically indeterminate cases require biop-
sy, with a further treatment according to the results of 
pathological examination (biopsy of a part of lesion or 
a full excisional biopsy — the latter can be additionally 
considered as therapeutic in some cases). 
Suspicion of the local invasion (deep infiltration of 
surrounding tissues and structures, e.g. muscles, bones, 
nerves, lymph nodes or eye bulb) require further evalu-
ation with radiological imaging (computed tomography 
or magnetic resonance imaging). Presence of clinically or 
radiologically detected enlarged lymph nodes should be 
verified with fine-needle biopsy or an excision of a whole 
lymph node [1–6, 9–11].
Evaluation of prognostic factors and staging
The next step includes evaluation of prognostic fac-
tors in a malignant lesion, which correspond with low 
or high relapse risk (Tables 4, 5) and a proper staging 
according to American Joint Committee on Cancer 
guidelines (revision from 2009 and 2017) (Table 6) 
[1–6, 9–11].
Treatment
The primary objective in the treatment of skin 
carcinomas is a complete and radical removal of all 
cancer tissues. Therefore, modalities with the highest 
probability of obtaining full radicality and the least risk 
of local failure should be preferred. 
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Table 2. Dermatoscopic signs of BCC/SCC and their differentiation (based on [7])
Dermatoscopic  
signs of non- 
-melanocytic BCC 
Dermatoscopic 
signs of 
melanocytic BCC
Dermatoscopic signs  
of non-melanocytic SCC
Dermatoscopic signs of 
melanocytic SCC
Ea
rl
y 
st
ag
e
— Light rose/rose 
unstructured area
— Irregular, small 
vessels within 
lesion
— Thin, branching 
microvessels/ 
/telangiectasias/ 
/small, atypical, 
irregular vessels 
within white areas 
of lesion
— Corkscrew vessels 
— Small ulcerations
— Small eschars
— White shining dots 
and streaks (visible 
in polarised light)
— Grey-blue dots, 
spots, and 
balls
— Brown or rose 
balls 
— “Wheel with 
spokes” 
structures
— Brown or 
grey-blue 
“maple leaf” 
structures
— + Non- 
-melanocytic 
early BCC signs
Non-melanocytic actinic keratosis
On face: 
— “strawberry pattern” = white dots on rose 
background = rose/red pseudo-network
— white or yellow scale on surface of lesion
— thin, corrugated, twisted vessels surrounding 
follicular openings 
— white annuluses surrounding yellowish plugs 
located in a follicular opening
— white rosette in follicular opening (visible in 
polarised light)
Outside of face:
— white/yellow scale on surface
— thin, irregular telangiectasias 
Bowenoid actinic keratosis: 
Glomerular vessels covering surface of lesion
Bowen’s disease (SCC in situ):
— white/yellow scale of surface
— glomerular vessels in clusters; those vessels 
can be visible as red dots or balls
— small ulcerations/eschars 
Melanocytic actinic 
keratosis:
On face: 
— asymmetric colouring of 
follicular openings
— annular-granular 
— rhomboidal structures
— pseudo-network 
consisting of yellowish 
corneal plugs in follicular 
openings surrounded by 
grey halo
Melanocytic form of 
Bowen disease  
(SCC in situ):
— brown or grey dots 
forming radiant lines  
in perimeter
— rose or colourless, 
structureless, 
pigmentations situated 
peripherally
— glomerular vessels/red 
dots situated randomly 
or in clusters in perimeter
— desquamation of lesion 
surface
A
d
va
n
ce
d
 s
ta
g
e
— Thick, sharply 
branching 
vessels visible in 
perimeters, directed 
towards centre of 
lesion
— Ulceration
— Eschar
— White, shining 
dots and streaks, 
“rainbow” sign 
(visible in polarised 
light)
— Huge, grey- 
-blue nests of 
oval/oviform 
structures 
— + Non- 
-melanocytic 
advanced BCC 
signs
— Centrally located yellow plug/keratin mass/ 
/ulceration surrounded concentrically by 
“hairpin” vessels/irregular linear vessels
— White annulus on white/rose background
— Vessels (polymorphic) surrounded by white 
halo
— Eschars — red/orange/brown/even black/ 
/ulcerations
— In central part of lesion structure typical for 
early lesions might be found
— Extensive bluish 
colouring
— Irregularly distributed 
blue and grey granular 
structures
— If ulceration present: 
formation of black or 
dark brown eschar
— Poorly visible vessels
D
if
fe
re
n
ti
at
io
n
— Melanoma/other 
cancer metastases
— Spitz nevus
— Dermal rose/skin 
colour nevus
— Nevus
— Melanoma
— Melanoma 
metastases
— Seborrheic 
keratosis
— Spitz nevus
— Non-melanocytic BCC 
— Melanoma
— Keratoacanthoma
— Melanoma/LMM  
(on face)
— Melanocytic BCC
— Lichen keratosis
BCC — basal cell carcinoma; SCC — squamous cell carcinoma; LMM — lentigo maligna melanoma
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Table 3. Classification of actinic keratosis currently considered as IEN or SCC in situ(based on [14–16])
Broadness and number  
of actinic keratosis (AK) 
lesions
Histopathologic appearance Clinical appearance
Single AK lesions
≥ 1 and ≤ 5 palpable or visible 
lesions on a certain body part/
skin area
I type AK = early SCC in situ
Presence of atypical keratinocytes in basal layer and lower 1/3 of 
epidermis 
Stage I — mild
Lesions more palpable 
than visible with bare 
eye
Multiple AK lesion
≥ 6 palpable or visible lesions on 
a certain body part/skin area
II type AK = early SCC in situ
Presence of atypical keratinocytes in lower 2/3 of epidermis
Stage II — moderate
Lesions are both visible 
and palpable
Cancerisation fields
≥ 6 AK palpable or visible lesions 
on a certain body part/skin area 
and vast areas of chronically sun-
damaged skin with hyperkeratotic 
changes
III type AK — Bowenoid AK/SCC in situ
Presence of atypical keratinocytes in lower 2/3 of epidermis up to 
whole epidermis thickness
Stage III — severe
Lesions are covered with 
hyperkeratotic scale and 
they are evident
Immunosuppressed patients 
with signs of AK
Any number and size of AK 
lesion with a concomitant 
immunosuppression
Invasive SCC
Nests of keratinocytes infiltrates dermis
Cancer cells are large, with an abundant eosinophilic cytoplasm 
and evident enlargement of nucleus
Different stages of keratosis present, keratin pearls might be visible
Depending on SCC differentiation cells might exhibit different 
pleomorphism, mitotic activity and squamous epithelium 
characteristics
Depending on pathological subtype different levels of 
inflammation and stromal reaction might be visible
Suspicion of invasive 
SCC 
When signs are present:
— major criteria: 
ulceration, infiltration, 
bleeding, size > 1 cm, 
rapid growth, erythema
— minor criteria: pain, 
pruritus, colouring, 
hyperkeratosis, palpable
AK — actinic keratosis; BCC — basal cell carcinoma; SCC — squamous cell carcinoma
Factors influencing treatment choice include:
 — clinical evaluation, including number and size of 
lesion;
 — histopathological type and subtype;
 — stage and grade of the tumour, as well as the risk of 
local and distant failure;
 — possible organ/part of the body function preservation 
and expected aesthetic effect;
 — treatment efficacy evaluated as relapse rate within 
both 4–6 months and 3–5 years (verified by a physical 
examination, dermatoscopy, and histopathological 
evaluation);
 — treatment tolerance (pain, length of the treatment, 
adverse events risk);
 — availability of specific treatment modality;
 — patients immunocompetence status;
 — patient preferences. 
Figure 1 shows the recommended diagnostic and 
treatment algorithm in case of skin carcinoma suspicion.
Surgical treatment is often the quickest and most 
efficient curative modality. However, adequate tre-
atment strategy demand consideration of patient’s 
age, comorbidities, psychological aspects of treat-
ment, and expected aesthetical outcomes. Therefore, 
some cases require modalities other than surgery 
(especially in cases with low relapse risk). Possible 
methods include: 
 — superficial treatment: 5-fluorouracil, imiquimod 
(modulator of immunological response used topi-
cally for 6–8 weeks), diclofenac, chemical peeling, 
or photodynamic therapy;
 — local treatment:
•	 without margin assessment: laser therapy, cryo-
therapy, electrocoagulation, radiotherapy;
•	 with margin assessment possible: radical surgi-
cal excision (alternatively Mohs micrographic 
surgery).
It should be emphasised that we currently lack good 
quality data regarding comparison of different methods 
used in skin carcinoma treatment. Most of the available 
publications apply only to cancers in locations associated 
with a low risk of relapse or low invasiveness. Surgery 
remains a “golden standard” of skin cancer treatment, 
with the exception of inoperable cases [1–13, 18].
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Table 4. Relapse risk factors for squamous cell carcinoma (SCC) [1–6, 9–11]
Risk factors for SCC local and distant relapse
Low-risk lesion High-risk lesion
Localisation and size Area L < 20 mm Area L ≥ 20 mm
Area M < 10 mm Area M ≥ 10 mm
Area H
Margins of the lesion Well-defined margins Indefinite margins
Primary or relapsed lesion Primary Relapsed
Immunosuppression No Yes
Prior radiotherapy or chronic inflammatory process 
within the lesion
No Yes
Rapid growth of the lesion No Yes
Neurological symptoms No Yes
Histopathological grading Low or intermediate grade
G1, G2
High grade
G3
Thickness of the lesion < 2 mm
I–III Clark’s level
≥ 2 mm
IV–V Clark’s level
Vascular or perineural invasion No Yes
Histopathological subtype Metatypicus
Verrucosus
Fusiformis
Mixtus
Acantholiticus
Desmoplasticus
Adenoidalis, adenoidosquamousus
Mucosoadenoidalis
Fusiformis (after radiotherapy)
Area L — torso and extremities with the exception of anterior surface of crus, hands, feet, ankles, and nails; area M — cheeks, forehead, hairy parts of head 
skin, neck, anterior surface of crus; area H — head and neck with an exception of M area, genital area, hands, and feet
Table 5. Relapse risk factors for basal cell carcinoma (BCC) [1, 17]
Relapse risk factors for BCC
Low-risk lesion High-risk lesion
Localisation and size Area L < 20 mm Area L ≥ 20 mm
Area M < 10 mm Area M ≥ 10 mm
Area H
Margins of the lesion Well-defined margins Indefinite margins
Primary or relapsed lesion Primary Relapsed
Immunosuppression No Yes
Prior radiotherapy No Yes
Histopathological subtype Superficial
Nodular
Fibroepithelioma
Keratotic
Folliculocystic
Cicatricial 
Sclerodermal
Metatypical
Infiltrating
Micronodular changes in any part of 
the lesion
Perineural invasion No Yes
Area L — torso and extremities with the exception of anterior surface of crus, hands, feet, ankles, and nails; area M — cheeks, forehead, hairy parts of head 
skin, neck, and anterior surface of crus; area H — head and neck with an exception of M area, genital area, hands, and feet
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Table 6. Staging of skin cancer (according to AJCC 2009) 
T stage (primary tumour)*
Tx The primary tumour cannot be evaluated 
T0 No evidence of primary tumour 
Tis Cancer in situ
T1 The tumour is 2 centimetres at its largest dimension with less than two high-risk factors#
T2 The tumour is more than 2 centimetres in its largest dimension 
OR 
Any size tumour with 2 or more high-risk factors#
T3 The tumour invades maxilla, mandibular, orbit, or temporal bone 
T4 The tumour invades spine or perineurally infiltrates skull base
*Does not apply to squamous cell carcinoma of an eyelid; #high-risk factors of the primary lesion (T stage)
High-risk factors
Deepness of the primary 
tumour infiltration
> 2 mm
Clark’s stage ≥ IV
Perineural invasion
Lesion location Auricle
Vermillion
Vermillion border
Differentiation Poorly differentiated or 
undifferentiated
N stage (regional lymph nodes) 
Nx Regional lymph nodes cannot be evaluated
N0 No evidence or lymph node involvement
N1 Single, ipsilateral lymph node involvement, with greatest dimension of lymph node ≤ 3 cm
N2 Single, ipsilateral lymph node involvement, with greatest dimension of lymph node > 3 cm but < 6 cm; 
OR
Multiple ipsilateral lymph nodes involved, without any lymph node longer than 6 cm in greatest 
dimension; OR
Bilateral or contralateral lymph node involvement, without any lymph node longer than 6 cm  
in greatest dimension 
N2a Single, ipsilateral lymph node involvement, with longest dimension of lymph node > 3 cm but < 6 cm
N2b Multiple ipsilateral lymph nodes involved, without any lymph node longer than 6 cm in longest 
dimension;
N2c Bilateral or contralateral lymph node involvement, without any lymph node longer than 6 cm in longest 
dimension
N3 Any lymph node involvement with more than 6 cm in greatest dimension
M stage (distant metastases)
M0 No evidence of distant metastases
M1 Distant metastases present
Æ
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TNM staging
Stage 0 Tis N0 M0
Stage I T1 N0 M0
Stage II T2 N0 M0
Stage III T3
T1
T2
T3
N0
N1
N1
N1
M0
M0
M0
M0
Stage IV T1
T2
T3
Any T
T4
Any T
N2
N2
N2
N3
Any N
Any N
M0
M0
M0
M0
M0
M1
Histopathological grading (G)
Gx Not evaluable
G1 Well differentiated
G2 Intermediately differentiated
G3 Poorly differentiated
G4 Undifferentiated
Additional classification of head and neck skin cancers (version from 2017)
T stage (main tumour mass)
Tx The primary tumour cannot be evaluated 
T0 No evidence of primary tumour 
Tis Cancer in situ
T1 The tumour is less than 2 cm in greatest dimension
T2 The tumour is between 2 and 4 cm in greatest dimension
T3 The tumour is more than 4 cm in greatest dimension with a minor bone invasion OR perineural invasion OR deep 
infiltration (no more than 6 mm of subcutaneous tissue invasion)
T4
T4a
T4b
Major infiltration of bones, the base of skull and/or skull foramens by the tumour
The tumour deeply infiltrates bones
The tumour infiltrates the base of skull and/or skull foramens
N stage (regional lymph nodes) 
Nx Regional lymph nodes cannot be evaluated
N0 No evidence or lymph node involvement
N1 Single, ipsilateral lymph node involvement, with greatest dimension of lymph node ≤ 3 cm and without extranodal extension
N2 Single, ipsilateral lymph node involvement, with greatest dimension of lymph node > 3 cm, but ≤ 6 cm; OR
Multiple ipsilateral lymph nodes involved, without any lymph node longer than 6 cm in greatest dimension; OR
Bilateral or contralateral lymph node involvement, without any lymph node longer than 6 cm in greatest dimension
All above without extranodal extension present
N2a Single, ipsilateral lymph node involvement, with greatest dimension of lymph node > 3 cm, but ≤ 6 cm without extranodal extension
N2b Multiple ipsilateral lymph nodes involved, without any lymph node longer than 6 cm in greatest dimension without 
extranodal extension
N2c Bilateral or contralateral lymph node involvement, without any lymph node longer than 6 cm in greatest dimension 
without extranodal extension
N3 Any lymph node involvement with more than 6 cm in greatest dimension and without extranodal extension OR any 
lymph node involvement with extranodal extension
N3a Any lymph node involvement with more than 6 cm in greatest dimension and without extranodal extension
N3b Any lymph node involvement with extranodal extension
Additionally, U or L mark might be use for, respectively, metastases above or below the lower margin of cricoid cartilage
Table 6 cont. Staging of skin cancer (according to AJCC 2009) 
Æ
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M stage (distant metastases)
M0 No evidence of distant metastases
M1 Presence of distant metastases
TNM staging
Stage 0 Tis N0 M0
Stage I T1 N0 M0
Stage II T2 N0 M0
Stage III T3
T1
T2
T3
N0
N1
N1
N1
M0
M0
M0
M0
Stage IV T1
T2
T3
Any T
T4
Any T
N2
N2
N2
N3
Any N
Any N
M0
M0
M0
M0
M0
M1
Histopathological grading (G)
Gx Not evaluable
G1 Well differentiated
G2 Intermediately differentiated
G3 Poorly differentiated
G4 Undifferentiated
Table 6 cont. Staging of skin cancer (according to AJCC 
2009) 
Skin cancer treatment — basic methods
Resection with histopathological evaluation of surgical 
margins
This is the most commonly used procedure in skin 
cancer treatment (in cases associated with both high- 
and low-risk of relapse). 
Surgical margin of at least 4 mm in cases of BCC and 
6 mm in cases of SCC is highly recommended (II, A). 
High-risk skin cancer requires additional intraoperative 
radicality evaluation (Mohs micrographic surgery). If 
such a procedure cannot be undertaken, wider exci-
sion with at least 10 mm of surgical margin is advised. 
When margins require resection of normal skin that 
would lead to unacceptable aesthetic effects, radical 
resection within narrower margins (R0 margin) might 
be considered. Such a margin might be achievable with 
a utilisation of Mohs micrographic surgery. In Mohs 
micrographic surgery the tumour is removed layer by 
layer, and each layer undergoes intraoperative histo-
pathological evaluation as a frozen specimen. Every 
excised layer is labelled in a fashion that allows further 
resection of those margins in which cancer cells are 
present. This procedure allows for a radical resection 
of the tumour with a maximal sparing of surrounding 
normal tissue [1–6, 9, 11, 13, 19, 20].
Radiotherapy
In case of non-melanocytic skin cancer (BCC and 
SCC), radiotherapy might be an alternative curative 
approach when surgical procedure is not feasible or 
not accepted by a patient (III, A). Additionally, it is the 
treatment of choice in inoperable cases, when specific 
aesthetic effect must be obtained, or when function 
preservation is priority (mainly in patients older than 
60). Radiation should be considered in tumours more 
than 5 mm in diameter located proximally to mouth, tip 
and flaps of nose, and more than 2 cm in proximity to 
ears, forehead, and scalp [21], especially when surgery 
would result in a major cosmetic defect. Effectiveness 
of radiotherapy is high, with five-year control rates of 
94.4% for BCC and 92.7% for SCC and 15-year control 
rates of, respectively, 84.8% and 78.6%, in retrospective 
data [22]. Available meta-analyses estimate the local 
relapse rate to be around 10% for both SCC and BCC 
[23–25]. However, trials comparing surgical treatment 
with radiotherapy in BCC suggest superiority of a sur-
gical approach, with a four-year local relapse rate of 
0.7% after surgery and 7.5% after radiotherapy [26]. In 
radical radiotherapy of skin cancers both conventional 
fractioning (60–70 Gy in 6–7 weeks or 45–55 Gy in 
3–4 weeks) and hypofractioning (40–44 Gy in 2 weeks 
or 30 Gy in 5 fractions for 2–3 weeks) might be used 
[27]. Adjuvant radiotherapy is used in locoregionally 
advanced skin cancer (especially if perineural invasion 
is present), after lymphadenectomy for locoregional 
lymph node involvement in SCC, and after non-radical 
surgical procedure when radicalisation with subse-
quent surgery is not feasible. Radiotherapy should 
be also considered after non-radical treatment with 
Mohs micrographic surgery. Additional risk factors for 
local recurrence include: head and neck localisation; 
lesion more than 2 cm in size; poor differentiation; 
previous recurrence; and immunosuppression [28]. 
Usually, 50–66 Gy in a period of 5–7 weeks is used 
in an adjuvant setting, with a higher dose delivered 
when surgical margins are positive or when unresected 
metastatic lymph nodes are present [27]. Radiotherapy 
is also a valuable option in the palliative treatment. 
In selected cases of superficial tumours (up to 2 cm 
depth) and after non-radical surgical procedures, 
brachytherapy might be an option.
The major disadvantage of radiotherapy includes 
the risk of adverse effects, which tend to exacerbate 
with time. Acute forms of radiation-induced skin re-
actions include erythema, dry or wet desquamation, 
or even skin necrosis, and chronic reactions usually 
take the form of telangiectasias, pigmentosus changes 
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Suspicious lesion:
1. History — Table 1
2. Examination of whole skin and supercial lymph 
nodes
3. Dermatoscopy
4. Biopsy in case of equvocal clinical or dermatoscopical  
status
5. Radiological imaging when distant metastases and/or 
involvement of local anatomical structures is 
suspected
6. Evaluation of relapse risk factors
Low-risk lesion
[without high-risk 
factors 
(Tables 4 and 5)]
 High-risk lesion 
[1 or more high-risk 
factors (Tables 4 and 5)]
Surgery 
feasible
Surgery not feasible 
or not accepted 
by the patient
Radiotherapy
Cryotherapy
5-uorouracil
Imiquimod 
once daily 
for 6–12 weeks 
Photodynamic 
method
Surgery 
feasible
Surgery not feasible 
or not accepted 
by the patient
Chirurgia 
mikrograczna 
Mohsa 
Radiotherapy
Vismodegib (localy 
advanced or metastatic 
BCC; possibly Gorlin-
-Goltz syndrome)
Chemotherapy (SCC)
Clinical trials 
if standard treatment 
methods fail 
or cannot be undertaken
*Smaller margin might be acceptable due to aesthetic requirements
Resection*
BCC margin 
(prefered) ≥ 4 mm
SCC margin ≥ 6 mm
Resection*
BCC margin 
(prefered) ≥ 4 mm
SCC margin ≥ 6 mm
Figure 1. Recommended diagnostic and treatment algorithm in case of skin carcinoma suspicion
(including persistent skin discolouration), and fibro-
sis. Due to this fact, aesthetic effects of radiotherapy 
might worsen with years. Additional adverse effects 
of radiotherapy include increased risk of radiation-
-induced secondary malignancies, mostly non-mela-
nocytic skin cancers, especially after irradiation at 
early age [29–31].
Contraindications for radiotherapy include:
 — age below 60 years (relative contraindication);
 — connective tissue disease (e.g. systemic lupus erythe-
matosus; scleroderma) (relative contraindication);
 — genetic syndromes associated with a high-risk of skin 
cancer [e.g. Gorlin-Goltz syndrome (naevoid basal 
cell carcinoma syndrome); xeroderma pigmentosum];
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 — cicatricial basal cell carcinoma;
 — tumours localised within hands (especially on dorsal 
surface), sole of foot, extremities (principally below 
knees and elbows);
 — recurrence after radiotherapy.
Chemotherapy
No data confirm the benefit of cisplatin, either as 
monotherapy or combination with 5-fluorouracil, in-
terferon, or cis-retinoic acid, in patients with metastatic 
SCC. Limited evidences suggest potential activity of 
EGFR inhibitors (such as cetuximab or gefitinib), but 
clinical application of those drugs requires further eva-
luation in clinical trials [1–5].
Hedgehog pathway inhibitors 
In patients with a genetic predisposition to develop 
multifocal BCC (Gorlin-Goltz syndrome), metastatic 
BCC, or locally advanced BCC refractory/unsuitable 
for surgical and radiotherapeutic approach, treatment 
with vismodegib (small molecule Hedgehog signalling 
pathway inhibitors) should be considered (II, A). 
Vismodegib, used at a daily dose of 150 mg, prolongs 
progression-free survival and achieves a response 
rate between 30 and 60%. Phase I–II trials confirmed 
vismodegib activity in advanced BCC and confirmed the 
response rates as mentioned. The ERIVANCE BCC 
clinical trial evaluated vismodegib (150 mg daily) in 
patients with metastatic BCC (mBCC) or locally advan-
ced BCC (laBCC; unresectable and/or unqualified for 
radiotherapy) [32]. The primary endpoint was overall 
response rate (ORR). An independent radiological 
assessment showed 33.3% ORR in the mBCC group 
and 47.6% ORR in the laBCC group (including 22.2% 
of complete responses). Median duration of response 
was 14.8 months in the mBCC group and 26.2 months in 
the laBCC group, and median progression-free survival 
was 9.3 months and 12.9 months, respectively. Most of 
the patients in both groups experienced a reduction of 
tumour size. Efficacy of vismodegib in this setting was 
confirmed in a large (> 500 patients) STEVIE trial, 
which showed similar results [33]. 
In a multicentre, randomised, placebo-controlled 
phase II trial (n = 41) activity of vismodegib in patients 
with Gorlin-Goltz syndrome was evaluated [34]. Deve-
lopment of new BCC lesions was significantly lower in 
patients receiving vismodegib compared to placebo (re-
spectively 2 vs. 29 new cases within a year). Additionally, 
reduction of already existing BCC lesions was seen in 
patients receiving vismodegib, without any case of BCC 
progression during vismodegib treatment. 
Vismodegib is used orally at a 150 mg dose once daily 
until disease progression or unacceptable toxicity (in 
Poland as part of a drug access programme). The most 
common adverse events (> 30% of patients) include mu-
scle cramps, taste alterations, decrease of body weight, 
fatigue, and nausea [1–4, 32, 35–38]. During and within 
the consequent 24 months after therapy cessation, usage 
of contraception is advised. Based on the results of the 
phase II BOLT trial, a novel Hedgehog pathway inhibi-
tor, sonidegib, is already registered within the USA [39].
Clinical trials
Patients with an advanced BCC or SCC, either local 
or systemic, who exhausted possible therapeutic options, 
should be offered inclusion in a clinical trial, if possible 
[1–5]. Currently recruiting trials evaluate PD-1 inhibitors 
(“checkpoint inhibitors”) in patients who progressed on 
Hedgehog pathway inhibitors. Several publications from 
the last 2–3 years suggest activity of immunotherapy with 
PD-1 inhibitors in patients with advanced BCC and SCC 
[40–46]. 
In a case described by Hauschild et al., a patient with 
type E xeroderma pigmentosum, four de novo melano-
mas, multiple invasive and non-invasive SCC, and with 
extended areas of cancerisation, received pembrolizu-
mab due to metastatic melanoma. The authors observed 
not only the response of melanoma metastases, but also 
a rapid decline of actinic keratosis areas and regression 
of invasive SCC [47].
Generally, treatment of advanced skin cancers with 
radiotherapy, chemotherapy, or targeted therapy should 
be performed at highly specialised and experienced 
cancer centres. 
Skin cancer treatment — superficial methods 
Cases of BCC and SCC associated with low-risk of 
recurrence might by treated with superficial methods. 
Due to the clear inferiority of such an approach, it sho-
uld be limited only to patients with contraindications 
to standard modalities (especially surgery). Superficial 
treatment might be also considered in patients with 
a shallow, low-risk BCC, when a significant benefit in 
aesthetic outcomes might be expected.
5-fluorouracil (0.5%)
The drug is used in the treatment of actinic keratosis, 
superficially growing BCC and SCC in situ. 5-fluoroura-
cil is applied twice daily for a period of 4, 6, or 11 weeks 
in cases of superficial forms of BCC, with a complete 
response obtained in about 90% of patients. In cases 
of actinic keratosis, the drug is used on average for 2–4 
weeks, with a complete response in 82% of skin changes. 
Imiquimod (5%)
The drug is used in the treatment of actinic keratosis, 
SCC in situ/Bowen disease, and for superficially growing, 
non-invasive cases of BCC. The cream is currently used 
for longer periods (12 weeks instead of 6) and applied 
more often (two times daily) because those prolonged 
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treatment results in lower rates of failure (III, A). 
Application as an occlusion in superficial and nodal 
forms of BCC up to 2 cm in size offers similar efficacy. 
About 84% of patients with a superficial form of BCC 
had no signs of disease after five years of follow-up. In 
immunocompetent patients the cream might be used as 
a sole modality, but in immunocompromised patients 
imiquimod should be combined with cryotherapy, Mohs 
microsurgery, or photodynamic method [1–6, 11–13, 
19, 20, 48].
Photodynamic method
This method is recommended in the treatment of 
skin cancer for: nodal and superficial forms of BCC; 
SCC in situ or Bowen disease; and actinic keratosis. 
Photodynamic treatment requires usage of delta-ami-
nolaevulinic acid (ALA) and methyl aminolaevulinate 
(MAL). The light source can be a laser or lamp. In 
a randomised, multicentre clinical trial the effects of 
the photodynamic method as a treatment for 601 cases 
of superficial BCC was evaluated. Tumour remission 
was obtained in 72.8% of cases treated with MAL-
-PDT (two session within a week) in comparison to 
83.4% of cases treated with imiquimod (five times in 
a week for six weeks) and 80.1% of cases treated with 
5-fluorouracil (two times per day for four weeks). Other 
trials confirmed the effectiveness (defined as a rate of 
complete responses after three months and two years) 
of the photodynamic method in the treatment of: actinic 
keratosis (93% and 69%, respectively); Bowen disease 
(93% and 68%, respectively); superficial BCC (93% 
and 85%, respectively); nodal form of BCC (75–82% 
and 77%, respectively, after 60 months of follow-up).
In 2013 a new consensus regarding the role of the 
photodynamic method in the treatment of patients 
with Gorlin-Goltz syndrome was published. Based on 
an analysis of nine papers summarising 83 cases, the 
photodynamic method was acknowledged as a safe and 
efficient treatment modality for superficial BCC and 
nodal BCC with a depth of infiltration less than 2 mm. 
The authors of the consensus recommended a schedule 
of follow-up depending on the number of BCC lesions, 
recurrence frequency, and lesion’s localization. One 
of the advantages of the photodynamic method is the 
option of simultaneous treatment of multiple lesions.
An analysis of randomised controlled trials eva-
luating the 12-month efficacy of local treatment for 
Bowen’s diseases was published in 2013. The lack of 
good quality quantitative data was highlighted. Analy-
sis of available results demonstrated higher efficacy of 
MAL-PDT compared to cryotherapy alone and similar 
results when compared to 5-FU alone or 5-FU and 
cryotherapy combined. 
A 2014 meta-analysis regarding treatment of actinic 
keratosis located within the head and neck showed 
similar efficacy of MAL-PDT when compared to other 
options. After three months of follow-up, PDT was 14% 
better than cryotherapy.
A systematic review from 2012 evaluated three-
-month and two-year efficacy of available modalities 
in the local treatment of actinic keratosis. Both three-
-month and two-year results were comparable between 
all analysed methods, with the best aesthetic effects 
obtained with PDT and imiquimod. The photodynamic 
method is recommended for limited skin areas because 
it showed better results than cryotherapy. Topical su-
perficial modalities (imiquimod, 5-FU, 3% diclofenac, 
ingenol mebutate) were recommended for vast areas 
of skin due to comparable efficacy [1–6, 17, 38, 48–52].
Cryotherapy
Cryotherapy leads to tumour necrosis via decrease 
of tissue temperature to between –50 and –600C. Its 
applications include the treatment of superficial skin 
cancer with low-risk of recurrence and size under 2 cm 
or lesions of actinic keratosis. Cryotherapy is not re-
commended in the treatment of nodular changes. As 
multiple different cryotherapy techniques are commonly 
used, head-to-head comparison of outcomes from dif-
ferent studies is vastly limited (IV, B) [1–6].
Commentary
Due to the lack of reliable scientific data based on 
randomised controlled trials, usage of curettage and 
electrodessication in the treatment of skin cancers is 
not recommended. 
For the same reasons, the Oncology Section of the 
Polish Society of Dermatology (Polskie Towarzystwo 
Dermatologiczne; PTD) and the Melanoma Academy 
Section of the Polish Society of Surgical Oncology (Pol-
skie Towarzystwo Chirurgii Onkologicznej; PTChO) do 
not recommend other tissue destructive methods (laser 
therapy, dermabrasion, chemical peeling with trichloro-
acetic acid) because they indispose proper evaluation 
of radicality. 
A few randomised trials evaluating the effectiveness 
of intratumourally administered interferon in BCC 
showed modest efficacy in the treatment of superficial 
and small nodal BCC, with a high rate of early failures 
(around 30%) and high rates of adverse events [1–6].
Observation after oncological treatment
The necessity for close follow-up after treatment for 
skin cancer arises from multiple conditions, including:
 — in about 30–50% of patients who develop skin can-
cer, a subsequent skin cancer will develop within 
next five years;
 — 70–80% of SCC recurrences will occur within the 
first two years of follow-up;
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 — patients who developed skin cancer have a 10-fold 
increase of developing subsequent skin cancer com-
pared to the general population; 
 — patients who developed skin cancer have a higher 
risk of developing melanoma;
 — immunocompromised/immunosuppressed patients 
have a higher risk of developing invasive forms of 
SCC.
Every suspicion of skin cancer recurrence should be 
verified by a histopathological examination. Dermato-
scopy often enables diagnosis of early-stage recurrence 
and precisely identifies the best site for biopsy. 
The presence of enlarged regional lymph nodes 
justifies at least fine-needle biopsy (less commonly 
excision of a whole lymph node for a histopathological 
examination) and proper radiological imaging (CT, 
MRI) as a method of staging.
Follow-up principles:
 — BCC or SCC
•	 whole-year photoprotection SPF 30–50+,
•	 patient’s self-control monthly,
•	 dermatological and dermatoscopic examination 
of whole skin surface every 4–6 months for five 
years and every 6–12 months thereafter;
 — locally advance or metastatic BCC/SCC
•	 whole-year photoprotection SPF 30–50+,
•	 patient’s self-control monthly,
•	 dermatological and dermatoscopic examination 
of whole skin surface: every 1–3 months in e year, 
every 2–4 months in the second year, every 4–6 
months in the third year, and every 6–12 months 
thereafter for life,
•	 multidisciplinary care (e.g.: dermatological, 
oncological, radiotherapeutic, neurological, 
ophthalmological).
Surveillance of patients after organ transplantation 
during chronic immunosuppressive treatment:
 — whole-year photoprotection SPF 30–50+;
 — patient’s self-control monthly;
 — dermatological and dermatoscopic examination of 
whole skin surface: every 6–12 months for life;
 — after skin cancer occurrence a control visit should 
be performer every 3–6 months for life.
Surveillance over patients with genetic predisposi-
tion for skin cancer development: 
 — whole-year photoprotection SPF 30–50+;
 — patient’s self-control monthly;
 — dermatological and dermatoscopic examination of 
whole skin surface: every 3–6 months for life;
 — in patients with xeroderma pigmentosum reversal 
of circadian rhythm might be deliberated and strict 
occupational avoidance of UV, IR, and X-ray radia-
tion should be recommended.
Skin cancer prevention
Primary prevention:
 — strict surveillance over patients with genetic predi-
sposition for skin cancers induced by UV radiation;
 — population-based education regarding proper skin 
photoprotection and skin cancer awareness.
Secondary prevention:
 — patient-aimed education regarding proper skin 
photoprotection;
 — patient-aimed education about signs and symptoms of 
skin cancer and the importance of systemic self-control;
 — regular dermatological control (including dermato-
scopy) according to a prearranged schedule;
 — in patients receiving immunosuppressants, who 
develop actinic keratosis and/or NMSC, consider 
reduction of calcineurin inhibitor/antimetabolite 
doses in favour of mTOR inhibitors.
Merkel-cell carcinoma (primary 
neuroendocrine carcinoma of skin)
Merkel-cell carcinoma (MCC) is a rare, but highly 
aggressive skin cancer that arises from neuroendocrine 
cells (Merkel cells) [54, 55]. 
The incidence rate of MCC is low and estimated at 
0.25–0.32 per 100,000 persons annually, with a higher 
prevalence in men than in women (ratio of 1.5:1). MCC 
occurs more often in Caucasians than in other races. The 
incidence rate rises with age, as MCC rarely develops 
in people younger than 50 years old, with a clear rise of 
incidence in people between 50 and 65 years old. The 
mean age at MCC diagnosis in men is five years lower 
than in women. The most common site of occurrence is 
the skin of the head and neck (44–48% of cases), then 
the skin of the upper (around 19% of cases) and lower 
extremities (between 16 and 20% of cases) [56, 57]. 
Most of the MCC cases arise from skin. Other sites 
of primary lesions (such as mucous membranes or me-
tastatic MCC with unknown primary site) are extremely 
rare [58].
Aetiology
The aetiology of MCC remains unknown, but several 
factors predisposing to MCC development have been 
well described. The most important of them include:
 — exposition to UV radiation [natural or artificial, such 
as phototherapy using psoralens (PUVA, psoralen 
ultraviolet A) for psoriasis] [59, 60];
 — diseases associated with immunosuppression, e.g.:
•	 HIV infection or AIDS (11-fold increase in risk 
of MCC) [61],
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•	 immunosuppression after organ transplant (five-
-fold increase in risk of MCC) [62, 63],
•	 chronic lymphatic leukaemia;
 — specific viral infections, with polyomavirus infection 
recognised most often (variant characteristic for 
MCC: Merkel cell polyomavirus, MCPyV) [64, 65].
Diagnosis
MCC usually forms as a rapidly growing tumour or 
solid skin infiltration, often red to violet in colour. Ulce-
rations occur rarely. Sometimes, due to a rapid spread 
through lymphatic vessels, satellite lesions develop. The 
tumour is often asymptomatic and, in most cases, not 
painful [66]. Because of this uncharacteristic clinical symp-
tomatology, MCC is rarely suspected before obtaining 
histopathological results from biopsy or excised specimens. 
Anglo-Saxon literature suggests a mnemotechnic 
acronym as an aid in MCC diagnostics — AEIOU (A — 
asymptomatic; E — expanding rapidly; I — immune 
suppressed; O — older than 50 years; U — UV-exposed 
skin). Only about 7% of MCC patients fulfil all criteria, 
but nearly 90% fulfil at least three of them [66]. 
Signs, symptoms, and brisk onset of lesion may sug-
gest malignant nature and should legitimise excisional 
biopsy, performed according to standard oncological 
procedures. Microscopic examination of the removed 
tumour allows a valid diagnosis. Pathological exami-
nation might be enhanced by immunohistochemical 
staining that allows differentiation of MCC from other 
small round-cell cancers. A typical immunoprofile of 
Merkel cell carcinoma is CKAE1/AE3(+), CK20(+), 
CD56(+), synaptophysin(+/–), chromogranin(+/–), 
NSE(+), LCA(–), TTF1(–), CDX2(–), p40(–). 
MCC diagnosis requires retaking of physical exami-
nation and obtaining additional radiological imaging to 
assess the stage of the disease. Depending on individual 
indications, radiological assessment [X-rays, computed 
tomography (CT), magnetic resonance imaging (MRI)] 
might be combined with a pathological or cytological 
(fine-needle biopsy) evaluation of suspicious lesions. 
In some cases, when results from histopathological 
examination are dubious and when systemic spread of 
disease is suspected (skin metastases of other than MCC 
neuroendocrine neoplasms, e.g. small-cell lung cancer), po-
sitron emission tomography-computed tomography (PET-
-CT) might be indicated and provide valuable clinical data. 
Staging and prognosis
Staging is assessed according to American Joint 
Committee on Cancer (AJCC) 8th edition from 2017, 
which is based on typical TNM (tumour-node-me-
tastases) criteria (Tables 7, 8) [58, 67–70]. The most 
Table 8. Staging/prognostic groups
Staging
T N M
0 Tis N0 M0
I T1 N0 M0
IIA T2–T3 N0 M0
IIB T4 N0 M0
IIIA T0 N1b M0
IIIA Any T N1a(sn)/N1a M0
IIIB Any T N1b–N3 M0
IV Any T Any N M1
Table 7. MCC staging (AJCC 8th edition; 2017)
Primary tumour (T)
TX The primary tumour cannot be assessed
T0 No evidence of primary tumour (e.g. nodal/metastatic 
presentation without associated primary tumour)
Tis In situ primary tumour
T1 Maximal tumour diameter less than or equal to 2 cm
T2 Tumour diameter greater than 2 cm, but less than or 
equal to 5 cm
T3 Tumour diameter greater than 5 cm
T4 Primary tumour invades bone, muscle, fascia, or 
cartilage
Regional lymph nodes (N)
NX Regional lymph nodes cannot be assessed
N0 No regional lymph node involvement
N1 Metastatic involvement of regional lymph nodes
N1a 
(sn)
Micrometastasis (sentinel lymph node biopsy)
N1a Clinical detection negative; presence of lymph node 
metastasis in pathologic examination
N1b Clinical detection positive (physical examination or 
radiological evaluation), confirmed in pathologic 
examination
N2 In transit metastases without lymph node involvement
N3 In transit metastases with lymph node involvement
Distant metastases (M)
M0 No distant metastasis
M1 Distant metastases present (beyond regional lymph 
node)
M1a Metastases to skin, subcutaneous tissues, or distant 
lymph nodes
M1b Metastases to lung
M1c Metastases to all other visceral organs
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important prognostic factors include size of primary 
lesion, range of lymphatic node involvement, and the 
presence of distant metastases.
Currently, 10-year survival rates for MCC are esti-
mated to be around 65% in women and 50.5% in men 
(with a mean of about 57% for both sexes). Depending 
on the size of primary lesion 10-year survival rates are: 
for cancers less than and equal to 2 cm in diameter — 
61%; for cancer greater than 2 cm in diameter — only 
39% [58].
Treatment
The standard treatment for locoregionally limited 
MCC is surgery. Treatment of MCC should be limited 
to highly specialised cancer centres [13, 68, 71, 72].
Stage I and II
In case of no signs of regional lymph node involve-
ment, sentinel lymph node biopsy and a wide excision 
(with at least 1–2 cm margin) of a scar should be con-
sidered, with a possible addition of adjuvant radiothe-
rapy. Metastases in sentinel lymph nodes are present 
in around 25–35% of patients with negative clinical 
examination. The risk of micrometastases presence rises 
significantly with the diameter of the primary lesion 
greater than 1 cm [73, 74].
Stage III
In cases with regional lymph node involvement (both 
micro- and macrometastases; stage III), a regional lym-
phadenectomy is recommended. 
Despite the lack of evidence from randomised, con-
trolled trials, available retrospective data suggest that 
adjuvant radiotherapy (at a dose of 50–60 Gy) results 
in improved locoregional disease control and improved 
overall survival (III, B) [75, 76].
Some authors suggest that in patients with a bulky 
nodal metastases, chemotherapy might provide bene-
fit. No standard systemic treatment schedule exists in 
this group because the treatment might be delivered 
in both neoadjuvant and adjuvant settings. In some 
cancer centres lymphadenectomy is performed between 
chemotherapy cycles. Nevertheless, available data is 
insufficient to define the magnitude of benefit derived 
from chemotherapy in a bulky stage III MCC [76–78].
Stage IV
Treatment of advanced, metastatic MCC has pal-
liative character. Patients with sufficient performance 
status might receive palliative chemotherapy, despite 
the lack of data regarding efficacy and survival benefit 
from this kind of treatment (not including immunothe-
rapy) [68, 79]. Several observations indicate a degree 
of chemosensitivity of MCC, although duration of 
responses does not exceed 8–10 months and with low 
rates of long-term survival (0–18%). Chemotherapy 
regimens commonly used include polychemotherapy 
with cisplatin, doxorubicin, and vincristine or etopo-
side, as well as 5-fluorouracil or cyclophosphamide. 
Palliative surgical or radiotherapeutic procedures can 
be used if indicated. 
Due to the high efficacy of immune check-point 
inhibitors (mostly antibodies aimed at PD-1 and PD-L1 
receptors), verified in phase II clinical trials, current 
guidelines recommend them as a treatment of choice 
in metastatic MCC (II, A). 
Nevertheless, as available data regarding treatment 
of MCC are insufficient to unequivocally derive a clear 
standard of care (especially in metastatic setting), parti-
cipation in clinical trials should be strongly encouraged.
The single-arm, phase II trial Javelin Merkel 200 
showed an impressive efficacy of avelumab in meta-
static MCC after chemotherapy failure, which allowed 
prompt registration of avelumab in this indication 
(at a dose of 10 mg/kg of body weight, administered 
intravenously every two weeks until progression or 
unacceptable toxicity). Objective response rate re-
ached 31.8% [95% confidence interval (CI) 21.9–43.1; 
28 patients], including eight complete responses (9%) 
and 20 partial responses (23%). An additional nine 
patients (10%) achieved stable disease [80]. Responses 
were durable and were ongoing in 23 (82%) patients 
at the time of analysis. In 92% of patients the dura-
tion of response was longer than six months. Median 
progression-free survival (PFS) was 2.7 months (95% 
CI 1.4–6.9) and the rate of progression-free survival at 
six months reached 40%. The PFS curve reached a pla-
teau. The rate of six-month overall survival was 69% 
(95% CI 58–78), and the median OS was 11.3 months 
(95% CI 7.5–14.0). Objective response was noted in 
20 out of 58 patients (34.5%) with positive PD-L1 
expression, in three out of 16 (18.8%) PD-L1-negative 
patients, in 12 out of 46 (26.1%) MCPyV(+) patients, 
and in 11 out of 31 (35.5%) MCPyV(–) patients. More 
responses were seen in patients who received only one 
prior line of systemic therapy. Treatment with avelu-
mab was generally well tolerated. Treatment-related 
adverse events occurred in 62 (70%) out of 88 patients. 
Treatment-related grade 3 adverse events developed 
as five events in four patients (5%): lymphopaenia 
in two patients, increase in creatine phosphokinase 
in one patient, increase in aminotransferases in one 
patient, and increase in cholesterol in one patient. No 
grade 4 toxicities or treatment-related deaths were 
observed. Serious treatment-related adverse events 
were noted in five patients (6%): colitis, drug infusion 
reaction, increase in aminotransferases, synovitis, and 
interstitial nephritis (each in one case). Potentially im-
munological-mediated adverse events included hypo-
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thyroidism (3%), hyperthyroidism (2%), pneumonitis 
(1%), and type 1 diabetes (1%). Two patients stopped 
the treatment due to adverse events (2%). Another 
phase II trial, with results published in 2016, evaluated 
pembrolizumab, an anti-PD-1 antibody, in treatment 
naïve, stage IIIB–IVC patients with MCC [81]. The 
trial included 26 patients treated with pembrolizumab 
(at a dose of 2 mg/kg of weight every three weeks) in 
a first-line treatment of metastatic MCC. The objective 
response rate reached 56% (four complete responses 
and 10 partial responses), and progression developed 
only in two out of 14 responding patients after a medial 
follow-up of 33 weeks. As with avelumab, responses 
occurred irrespectively of MCPyV status. The rate of 
six-month PFS was 67%. Analysing those two trials, it 
seems that there is a tendency towards higher response 
rates with fewer prior lines of treatment. Therefore, 
immunotherapy should be considered the treatment of 
choice in first-line treatment of metastatic MCC, espe-
cially considering the results from the pembrolizumab 
trial. Responses were achieved irrespective of MCPyV 
status, and immunotherapy proved to be effective even 
in older patients, which is common for MCC.
Treatment of local and locoregional recurrence
Local and locoregional recurrence are the most 
common forms of relapse and occur in nearly 30% of 
surgically treated patients (adjuvant radiotherapy redu-
ces this rate to about 11%) [82].
Local and locoregional recurrence might be treated 
as primary MCC with adequate stage (I–III). If possible, 
the tumours should be resected with an appropriate 
surgical margin, and adjuvant radiotherapy should be 
considered if not given previously. Because relapse is 
associated with an inferior prognosis, adjuvant systemic 
therapy might be considered, despite the lack of data 
confirming benefit from such a treatment.
Other rare forms of skin cancer 
Sebaceous carcinoma
This type of cancer arises from sebaceous glands and 
develops most commonly in the 7th decade of life. It is 
usually localised in the periocular region, sometimes 
as part of Muir-Torre syndrome. In early form it mimic 
chalazion or blepharitis, a common reason for delay 
in diagnosis. The primary tumour is usually treated 
surgically. Due to a 40% rate of regional lymph node 
involvement, some centres perform sentinel lymph node 
biopsy with a subsequent lymphadenectomy if indicated 
[83, 84]. No efficient systemic treatment exists. Nearly 
22% of patients dies due to the development of distant 
metastases [85, 86].
Primary cutaneous apocrine carcinoma (apocrine 
adenocarcinoma)
Primary cutaneous apocrine carcinoma develops in 
periorbital, axillar, genital, and perianal areas of skin. 
The primary lesion often develops proximally to Paget’s 
disease foci located outside of the breast. The presence 
of regional lymphatic node metastases and a tendency 
towards local recurrences were described. Therefore, 
besides radical resection with a wide margin, a sentinel 
lymph node biopsy is recommended [87–89].
Eccrine carcinoma (also syringoid carcinoma)
Eccrine carcinomas form nodular tumours, located 
mostly on the skin of the head and upper extremities, 
and characterised by various growth dynamics. It usually 
affects people over 50 years old. Several subtypes can 
be distinguished, with different occurrence rates and 
clinical aggressiveness (MAC, microcystic adnexal car-
cinoma; eccrine porocarcinoma; hidrade- nocarcinoma; 
spiradenocarcinoma; eccrine mucinous carcinoma; ma-
lignant eccrine spiradenoma; malignant mixed tumour; 
malignant cylindroma; syringoid carcinoma) [90]. The 
most common subtype, MAC, requires vast, radical 
excision of the primary lesion or MMS procedure, due 
to its aggressive growth and a high relapse rate [91]. 
Inoperable lesions might be treated with radiotherapy. 
In other subtypes of eccrine carcinoma locoregional and 
distant metastases were observed in up to 60% of cases. 
A few publications suggest limited benefit from systemic 
treatment with cytotoxic drugs [92].
Cancer originating from hair follicle:  
trichilemmal carcinoma, trichoblastic carcinoma, 
malignant proliferating trichilemmal cyst,  
pilomatrix carcinoma
Surgery is a fundamental treatment modality. Due 
to its rare occurrence, no significant data regarding 
systemic therapy exists.
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